Effect of b value on monitoring therapeutic response by diffusion-weighted imaging

Jiang, Zhaoxia; Peng, Wei; Li, Wen Tao; Tang, Feng; Liu, Shi Yuan; Qu, Xudong; Wang, Jianhua; Li, Hong

doi:10.3748/wjg.14.5893

Cited by 15 publications

(4 citation statements)

References 29 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For tumours that exhibit considerable heterogeneity (e.g. mixed solid, necrotic and cystic), some authors have suggested using multiple ROIs to evaluate sub-regions within these tumours [ 44 ] . However, there may be subjectivity and bias in such ROI placements.…”

Section: Diffusion-weighted Mr Imaging (Dwi) For Assessing Tumour Resmentioning

confidence: 99%

Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?

Afaq¹

2010

Cancer Imaging

View full text Add to dashboard Cite

Diffusion-weighted magnetic resonance imaging (DWI) is increasingly being used to assess tumour response to a variety of anticancer treatments. The technique is quick to perform without the need for administration of exogenous contrast medium, and enables the apparent diffusion coefficient (ADC) of tissues to be quantified. Studies have shown that ADC increases in response to a variety of treatments including chemotherapy, radiotherapy, minimally invasive therapies and novel therapeutics. In this article, we review the rationale of applying DWI for tumour assessment, the evidence for ADC measurements in relation to specific treatments and some of the practical considerations for using ADC to evaluate treatment response.

show abstract

Section: Diffusion-weighted Mr Imaging (Dwi) For Assessing Tumour Resmentioning

confidence: 99%

Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?

Afaq¹

2010

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…It enables quantitative analyses by measuring the standard apparent diffusion coefficient (ADC) value. Thus, this technique can be used to evaluate TACE response for HCC [9]- [14]. But conventional DWI with a mono-exponential model could not separate perfusion and true diffusion-related effect.…”

Section: Introductionmentioning

confidence: 99%

Intravoxel Incoherent Motion Diffusion Weighted Imaging for the Therapeutic Response of Transarterial Chemoembolization for Hepatocellular Carcinoma

Peng¹,

Yang²,

Zheng³

et al. 2019

JCT

View full text Add to dashboard Cite

Background: Intravoxel incoherent motion diffusion weighted imaging (IVIM-DWI) can not only observe the diffusion of tissue water molecules but also reflect the blood perfusion information of tissue microcirculation. IVIM-DWI has been applied in many clinical areas. However, few studies have addressed the use of IVIM-DWI for the evaluation of transarterial chemoembolization (TACE) response in hepatocellular carcinoma (HCC) patients. Objectives: The purpose of the present study was to explore the role of IVIM-DWI for the therapeutic response of TACE for HCC. Materials and Methods: Twenty patients underwent IVIM-DWI scan on a 3.0T magnetic resonance imaging instrument 1-3 days before and 30 to 40 days after TACE. The values of IVIM-DWI parameters, including standard apparent diffusion coefficient (ADC), pure diffusion coefficient (Dslow), pseudo-diffusion coefficient (Dfast) and perfusion fraction (ƒ) were measured. The values of IVIM-DWI parameters before and after TACE were compared using paired t tests. The values between responsive and non-responsive groups were compared using independent-samples t test. P < 0.05 indicated statistical significance. Results: After TACE, the ADC and Dslow values in the tumors increased significantly, and the values of Dfast decreased significantly, while the values of f value did not change obviously. The ADC values in responsive group were remarkably higher than those in non-responsive group, the Dfast values in responsive group were significantly lower than those in non-responsive group, but the values of Dslow and f between the two groups were not different significantly.

show abstract

“…However, it is not applicable for patients with contraindications to MR imaging. Respiratory motion is a major issue in hepatic perfusion imaging ( 31 32 ). Second, in the present study, the RECIST (Version 1.1) criteria based on tumor size, but not the mRECIST based on tumor enhancement, were used for evaluating therapeutic response to TACLI.…”

Section: Discussionmentioning

confidence: 99%

CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers

Han

Cheng

et al. 2015

Korean J Radiol

View full text Add to dashboard Cite

ObjectiveTo prospectively evaluate the performance of computed tomography perfusion imaging (CTPI) in predicting the early response to transarterial chemo-lipiodol infusion (TACLI) and survival of patients with colorectal cancer liver metastases (CRLM).Materials and MethodsComputed tomography perfusion imaging was performed before and 1 month after TACLI in 61 consecutive patients. Therapeutic response was evaluated on CT scans 1 month and 4 months after TACLI; the patients were classified as responders and non-responders based on 4-month CT scans after TACLI. The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI. The optimal parameter and cutoff value were determined. The patients were divided into 2 subgroups according to the cutoff value. The log-rank test was used to compare the survival rates of the 2 subgroups.ResultsFour-month images were obtained from 58 patients, of which 39.7% were responders and 60.3% were non-responders. The percentage change in hepatic arterial perfusion (HAP) 1 month after TACLI was the optimal predicting parameter (p = 0.003). The best cut-off value was -21.5% and patients who exhibited a ≥ 21.5% decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001).ConclusionComputed tomography perfusion imaging can predict the early response to TACLI and survival of patients with CRLM. The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.

show abstract

Effect of b value on monitoring therapeutic response by diffusion-weighted imaging

Cited by 15 publications

References 29 publications

Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?

Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?

Intravoxel Incoherent Motion Diffusion Weighted Imaging for the Therapeutic Response of Transarterial Chemoembolization for Hepatocellular Carcinoma

CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers

Contact Info

Product

Resources

About